Osteoarthritis - Pipeline Review, H2 2011

Published by: Global Markets Direct

Published: Sep. 28, 2011 - 105 Pages


Table of Contents

Introduction
Global Markets Direct Report Coverage
Osteoarthritis Overview
Therapeutics Development
An Overview of Pipeline Products for Osteoarthritis
Osteoarthritis Therapeutics under Development by Companies
Osteoarthritis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Osteoarthritis Therapeutics - Products under Development by Companies
Osteoarthritis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Osteoarthritis Therapeutics Development
Abbott Laboratories
Osiris Therapeutics, Inc.
AlphaRx, Inc.
Antares Pharma, Inc.
Sanofi-Aventis
GlaxoSmithKline plc
A.P. Pharma, Inc.
Novartis AG
Dong-A Pharmaceutical Co., Ltd.
Glenmark Pharmaceuticals Ltd.
Mitsubishi Chemical Holdings Corporation
Pfizer Inc.
Warner Chilcott Limited
TransPharma Medical Ltd.
Menarini Group
Geron Corporation
Merck KGaA
Bone Medical Limited
Addex Pharmaceuticals
IntelGenx Technologies Corp.
Can-Fite BioPharma Ltd.
Medivir AB
Mesoblast Ltd
NicOx SA
Nuvo Research Inc.
Osteologix, Inc.
Pharmos Corporation
CombinatoRx, Incorporated
Galapagos NV
CrystalGenomics, Inc.
Simcere Pharmaceutical Group
AnaMar Medical AB
Jenrin Discovery, Inc.
IDEA AG
Grunenthal GmbH
Quigley Pharma, Inc.
Amura Holdings Ltd.
IMMD Inc.
PLx Pharma Inc.
TissueGene, Inc.
Rottapharm SpA
Nordic Bioscience a/s
Logical Therapeutics, Inc.
Omeros Corporation
Iroko Pharmaceuticals, LLC
Cellerix, S.A.
Phytomedics, Inc.
Viromed Co., Ltd.
TOKUHON Corporation
Cellceutix Pharmaceuticals, Inc.
Eurofarma
Nucitec, S.A. de C.V.
Mantecorp Industria Quimica e Farmaceutica Ltda
Stempeutics Research Private Limited
Ampio Pharmaceuticals, Inc.
Osteoarthritis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles
SMC021 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Iguratimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Diractin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Naproxcinod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Joicela - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Curcuma Domestica Extracts - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Derris Scandens Benth Extracts - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Glucosamine + Chondroitin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LT-NS001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synvisc - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methotrexate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Preparation Rich In Growth Factors - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GW406381 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hydroxychloroquine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sodium Hyaluronate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hydrocortisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Kondrium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Kondrium f - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Glucosamine Sulfate + Chondroitin Sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Platelet Rich Plasma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Corticosterone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dextrose - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alendronate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hydroxychloroquine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IP 889 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PG 201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Osteoarthritis Therapeutics - Drug Profile Updates
Osteoarthritis Therapeutics - Discontinued Products
Osteoarthritis - Featured News
Jul 05, 2011: Ampio Pharmaceuticals Announces Treatment Of First Patient In Phase Ib Ampion-In -Knee Trial For Osteoarthritis In Australia
May 31, 2011: Ampio Pharmaceuticals Initiates Phase IB Clinical Trial For Ampion
May 31, 2011: CrystalGenomics Initiates CG100649 Phase IIb Study In Patients With Osteoarthritis
May 19, 2011: TissueGene Initiates Patient Enrollment For Phase II Study Of TG-C For Osteoarthritis Of Knee
Apr 20, 2011: NicOx Withdraws Marketing Authorization Application For Naproxcinod In Europe
Apr 19, 2011: Novartis Withdraws Marketing Authorisation Application For Joicela
Mar 30, 2011: Astellas Submits Supplemental New Drug Application For Celecox Tablet In Japan
Jan 11, 2011: TransPharma Announces Successful Results Of A Phase 1 Clinical Trial of ViaDerm-Calcitonin For The Treatment Of Musculoskeletal Disorders
Jan 10, 2011: BioTime's CEO Michael West Presented Preclinical Data On OTX-CP03 And OTX-CP07 For The Treatment Of Osteoarthritis At STEM 2011 In Gurgaon, India
Jan 10, 2011: BioTime's CEO Michael West Presented Preclinical Data On OTX-CP03 And OTX-CP07 For The Treatment Of Osteoarthritis At STEM 2011 In Gurgaon, India
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Osteoarthritis, H2 2011
Products under Development for Osteoarthritis - Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Abbott Laboratories, H2 2011
Osiris Therapeutics, Inc., H2 2011
AlphaRx, Inc., H2 2011
Antares Pharma, Inc., H2 2011
Sanofi-Aventis, H2 2011
GlaxoSmithKline plc, H2 2011
A.P. Pharma, Inc., H2 2011
Novartis AG, H2 2011
Dong-A Pharmaceutical Co., Ltd., H2 2011
Glenmark Pharmaceuticals Ltd., H2 2011
Mitsubishi Chemical Holdings Corporation, H2 2011
Pfizer Inc., H2 2011
Warner Chilcott Limited, H2 2011
TransPharma Medical Ltd., H2 2011
Menarini Group, H2 2011
Geron Corporation, H2 2011
Merck KGaA, H2 2011
Bone Medical Limited, H2 2011
Addex Pharmaceuticals, H2 2011
IntelGenx Technologies Corp., H2 2011
Can-Fite BioPharma Ltd., H2 2011
Medivir AB, H2 2011
Mesoblast Ltd, H2 2011
NicOx SA, H2 2011
Nuvo Research Inc., H2 2011
Osteologix, Inc., H2 2011
Pharmos Corporation, H2 2011
CombinatoRx, Incorporated, H2 2011
Galapagos NV, H2 2011
CrystalGenomics, Inc., H2 2011
Simcere Pharmaceutical Group, H2 2011
AnaMar Medical AB, H2 2011
Jenrin Discovery, Inc., H2 2011
IDEA AG, H2 2011
Grunenthal GmbH, H2 2011
Quigley Pharma, Inc., H2 2011
Amura Holdings Ltd., H2 2011
IMMD Inc., H2 2011
PLx Pharma Inc., H2 2011
TissueGene, Inc., H2 2011
Rottapharm SpA, H2 2011
Nordic Bioscience a/s, H2 2011
Logical Therapeutics, Inc., H2 2011
Omeros Corporation, H2 2011
Iroko Pharmaceuticals, LLC, H2 2011
Cellerix, S.A., H2 2011
Phytomedics, Inc., H2 2011
Viromed Co., Ltd., H2 2011
TOKUHON Corporation, H2 2011
Cellceutix Pharmaceuticals, Inc., H2 2011
Eurofarma, H2 2011
Nucitec, S.A. de C.V., H2 2011
Mantecorp Industria Quimica e Farmaceutica Ltda, H2 2011
Stempeutics Research Private Limited, H2 2011
Ampio Pharmaceuticals, Inc., H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Osteoarthritis Therapeutics - Drug Profile Updates
Discontinued Products
List of Figures
Number of Products under Development for Osteoarthritis, H2 2011
Products under Development for Osteoarthritis - Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Abstract

Osteoarthritis - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Osteoarthritis - Pipeline Review, H2 2011', provides an overview of the Osteoarthritis therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoarthritis. 'Osteoarthritis - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Osteoarthritis.
  • A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Osteoarthritis pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Osteoarthritis.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Osteoarthritis pipeline depth and focus of Osteoarthritis therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.


Get full details about this report >>
 
Learn more about this product


Price and delivery options
Search Inside Report

US: 800.298.5699

Int'l: +1.240.747.3093

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.